SABS - SAB Biotherapeutics, Inc.
1.79
0.070 3.911%
Share volume: 16,972
Last Updated: 05-09-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.03%
PREVIOUS CLOSE
CHG
CHG%
$1.72
0.07
0.04%
Summary score
34%
Profitability
35%
Dept financing
10%
Liquidity
43%
Performance
37%
Sector
Manufacturing
Industry
Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Long-term ratios 2021 - 2025
The data are presented for the financials results of the quarters of the last 4 years.
Return on equity
-22.98%
Return on assets
-15.81%
Return on sales
-2127.9%
Return on invested capital
-50.59%
Total debt ratio
37.38%
Debt ratio change over timeo
-1.19%
Current Ratio
2.54%
Quick Ratio
2.2%
Cash Position Ratio
1.68%
Short-term ratios 2024 - 2025
The data are presented for the financials results of the quarters of the last year.
Return on equity
0%
Return on assets
-12.96%
Return on sales
-3876.95%
Return on invested capital
0%
Total debt ratio
34.66%
Debt ratio change over timeo
-1.82%
Current Ratio
3.46%
Quick Ratio
0%
Cash Position Ratio
1.43%
Last quarter ratios 2025
The data are presented for the financials results of the last quarter.
Return on equity
0%
Return on assets
-13.61%
Return on sales
0%
Return on invested capital
0%
Total debt ratio
43.84%
Debt ratio change over time
0%
Current Ratio
1.69%
Quick Ratio
0%
Cash Position Ratio
0.58%
Performance ratios (change over 4 years) 2021 - 2025
The data are presented for the change financials results of the quarter of the last 4 years.
Return on equity
-65.48%
Return on assets
-82.54%
Return on sales
5473.56%
Return on invested capital
-20.56%
Total debt ratio
-119.27%
Debt ratio change over time
-1.19%
Current Ratio
-3.87%
Quick Ratio
-2.12%
Cash Position Ratio
-3.27%
Compare in sector
The following table compares the individual analyzes for the other top 3 stocks within the same industry.
| Long-term ratios | SABS | AMGN | GILD | BNTX |
|---|---|---|---|---|
| Return on equity | -22.98% | 18.97% | 6.3% | 14.13% |
| Return on assets | -15.81% | 3.05% | 3.04% | 13.28% |
| Return on sales | -2127.9% | 29.08% | 27.81% | 1.7% |
| Return on invested capital | -50.59% | 5.17% | 3.5% | -46.9% |
| Profitability | 0% | 81% | 55% | 45% |
| Total debt ratio | 37.38% | 92.73% | 66.91% | 19.17% |
| Debt ratio change over time | -1.19% | 21.88% | 144.36% | -1.07% |
| Dept financing | 10% | 29% | 43% | 5% |
| Current Ratio | 3.46% | 1.25% | 1.34% | 0% |
| Quick Ratio | 0% | 0.92% | 1.18% | 0% |
| Cash Position Ratio | 1.43% | 0.44% | 0.54% | 0% |
| Liquididy | 27% | 16% | 12% | 75% |
| Short-term ratios | SABS | AMGN | GILD | BNTX |
|---|---|---|---|---|
| Return on equity | 0% | 0% | 0% | 0% |
| Return on assets | -12.96% | 2.68% | 3.48% | 0% |
| Return on sales | -3876.95% | 21.68% | 28.93% | 0% |
| Return on invested capital | 0% | 0% | 0% | 0% |
| Profitability | 50% | 38% | 50% | 0% |
| Total debt ratio | 34.66% | 92.96% | 66.32% | 0% |
| Debt ratio change over time | -1.82% | 0% | 0% | 0% |
| Dept financing | 9% | 25% | 43% | 0% |
| Current Ratio | 3.46% | 1.25% | 1.34% | 0% |
| Quick Ratio | 0% | 0.92% | 1.18% | 0% |
| Cash Position Ratio | 1.43% | 0.44% | 0.54% | 0% |
| Liquididy | 50% | 36% | 44% | 0% |
